receptor β y1135  (Cell Signaling Technology Inc)

Journal: Cell reports

Article Title: STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts

doi: 10.1016/j.celrep.2025.116703

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Rabbit monoclonal, pIGF-I Receptor β (Y1135) , Cell Signaling , Cat# 3918; RRID:AB_10548764.

Techniques: Virus, Control, Recombinant, Western Blot, Staining, Plasmid Preparation, Software

Journal: Cell Death & Disease

Article Title: BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site

doi: 10.1038/cddis.2012.78

Figure Lengend Snippet: Autocrine activation of the IGF-1R pathway by IGF-1 in BRCA1-KD cells. ( a) Cells pretreated with siRNA (control versus BRCA1) were incubated with an anti-IGF-1-neutralizing antibody and their lysates were subjected to western blot analysis with indicated antibodies. ( b ) DU145 and MCF10A cells treated with siRNA (control versus BRCA1) were subjected to western blot analysis as in ( a ). ( c ) Cells pretreated with siRNA were incubated with BMS-536924 and changes of p-IGF-1R β , p-AKT, and p-GSK3 were monitored by western blot analysis. β -actin was used as a loading control

Article Snippet: Antibodies used in this study were as follows: BRCA1 (C-20) (sc-642) from Santa Cruz Biotechnology; phospho-GSK3 β (Ser9) (# 9323), GSK3 β (# 9332), phospho-Akt (Ser473) (# 9271), Akt (# 9272), phospho-IGF-1R β (Y1135) (# 3918) and IGF-1R β (# 3027) from Cell Signaling (Danvers, MA, USA); and β -actin (A1978) and horseradish peroxidase-conjugated secondary antibodies from Sigma.

Techniques: Activation Assay, Control, Incubation, Western Blot

Journal: Cell Death & Disease

Article Title: BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site

doi: 10.1038/cddis.2012.78

Figure Lengend Snippet: Sensitization of cells to IGF-1R inhibitors by BRCA1-KD. ( a ) MTT assays were performed to measure the viability of MCF7 cells pretreated with siRNA (control versus BRCA1) after an additional 48 h treatment of IGF-1R inhibitors (BMS-536924 or GSK1904529A). ( b ) Cells pretreated with siRNA as in a were treated with 1 μ M of IGF-1R inhibitors (OSI-906 or AG 1024) for 48 h and the viability of cells was measured by MTT assay. ( c ) Cells transfected with expression vectors (control versus BRCA1) were treated with 1 μ M of OSI-906, 10 μ M of AG 1024, or 1 μ M of BMS-536924 for 72 h and the viability of cells was measured by MTT assay. ( d ) ZR-75-1 cells, pretreated with siRNA (control versus BRCA1), were further treated with IGF-1R inhibitors (1 μ M of OSI-906, 1 μ M of BMS-536924, or 1 μ M of BMS-754807, respectively) for 48 h and cell viability was measured by MTT assay. ( a – d ) Representative data are shown as mean±S.E.M. from at least three independent experiments performed in triplicate. * P <0.05; ** P <0.01; and *** P <0.001

Article Snippet: Antibodies used in this study were as follows: BRCA1 (C-20) (sc-642) from Santa Cruz Biotechnology; phospho-GSK3 β (Ser9) (# 9323), GSK3 β (# 9332), phospho-Akt (Ser473) (# 9271), Akt (# 9272), phospho-IGF-1R β (Y1135) (# 3918) and IGF-1R β (# 3027) from Cell Signaling (Danvers, MA, USA); and β -actin (A1978) and horseradish peroxidase-conjugated secondary antibodies from Sigma.

Techniques: Control, MTT Assay, Transfection, Expressing

Journal: Cell Death & Disease

Article Title: BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site

doi: 10.1038/cddis.2012.78

Figure Lengend Snippet: Pharmacological inhibition of IGF-1-EREL-Luc reporter activity in BRCA1-KD MCF7 cells. ( a ) MCF7 cells, pretreated with wild-type IGF-1-EREL-Luc and BRCA1 siRNA, were further treated with an IGF-1 monoclonal antibody or a small-molecule IGF-1R inhibitor (OSI-906), an AKT translocation inhibitor (Perifosine), a PI3K inhibitor (BEZ235), or an antiestrogen (ICI182780) for 24 h and subjected to the luciferase reporter assay. Representative data from two independent experiments are shown as mean±S.E.M. ** P <0.01 and *** P <0.001. ( b ) Schematic diagram of the IGF-1/IGF-1R pathway regulation by BRCA1

Article Snippet: Antibodies used in this study were as follows: BRCA1 (C-20) (sc-642) from Santa Cruz Biotechnology; phospho-GSK3 β (Ser9) (# 9323), GSK3 β (# 9332), phospho-Akt (Ser473) (# 9271), Akt (# 9272), phospho-IGF-1R β (Y1135) (# 3918) and IGF-1R β (# 3027) from Cell Signaling (Danvers, MA, USA); and β -actin (A1978) and horseradish peroxidase-conjugated secondary antibodies from Sigma.

Techniques: Inhibition, Activity Assay, Translocation Assay, Luciferase, Reporter Assay